DGX - Quest Diagnostics Non-GAAP EPS of $1.98 beats by $0.08 revenue of $2.33B beats by $70M

• Quest Diagnostics press release ( NYSE: DGX ): Q4 Non-GAAP EPS of $1.98 beats by $0.08 .
• Revenue of $2.33B (-15.0% Y/Y) beats by $70M .
• FY2023 reported diluted EPS expected to be between $7.61 and $8.21; and adjusted diluted EPS expected to be between $8.40 and $9.00 vs. consensus of $8.65.
• "In 2023, our focus is on growing our base business and increasing our efforts to drive productivity and expand margins. Our guidance for the full year reflects continued growth in the base business, tailwinds from recent Medicare reimbursement changes, investments to accelerate growth, and declining COVID-19 revenues."

For further details see: